icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Once Daily Sofosbuvir (GS-7977) plus PEG/RBV In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection: The ATOMIC Study
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
Tarek Hassanein1, Eric Lawitz2, Israel Crespo3, Mitchell Davis4, Michael P. DeMicco5, David R. Nelson6, David Eric Bernstein7, Nezam Afdhal8, Ira M. Jacobson9, John M. Vierling10, Stuart C. Gordon11, Jane Anderson12, Robert H. Hyland12, Robert Hindes12, William T. Symonds12, Evguenia S. Svarovskaia12, Di An12, Efsevia Albanis13, Sanjeev Arora14, Kris V. Kowdley15; for the ATOMIC Investigators
1 Southern California Liver Centers, Coronado, CA; 2 Alamo Medical Research, San Antonio, TX; 3 Advanced Research Institute, Trinity, FL; 4 South Florida Center of Gastroenterology, Wellington, FL; 5 Advanced Clinical Research Institute, Anaheim, CA; 6 University of Florida, Gainesville, FL; 7 North Shore University Hospital, Manhasset, NY; 8 Beth Israel Deaconess Medical Center, Boston, MA; 9 Weill Cornell Medical College, New York, NY; 10 Baylor College of Medicine, Houston, TX; 11 Henry Ford Health Systems, Detroit, MI; 12 Gilead Sciences, Inc., Foster City, CA; 13 Mt. Sinai School of Medicine, New York, NY; 14 University of New Mexico, Albuquerque, NM; 15 Virginia Mason Medical Center, Seattle, WA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif